ArticleAntibiotics (Basel, Switzerland)2025
URO-RESIST: A Real-World Retrospective Study on Multidrug-Resistant Sepsis with Urinary Tract Infection, Clinical Predictors, Inflammatory Biomarkers, and Patient Outcomes.
Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies.Microorganisms · 2026Review
- Pyelonephritis Caused by Multidrug-Resistant Bacteria During Pregnancy: A Case-Control Study.Antibiotics (Basel, Switzerland) · 2026Article
- Microbiota and antibiotic exposure in sarcoidosis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis with Urinary Tract Infection (UTI) is a serious condition with high morbidity and mortality, increasingly complicated by multidrug-resistant (MDR) infections. Prompt diagnosis and appropriate treatment are key to improving outcomes and limiting antimicrobial resistance. The URO-RESIST study aimed to assess the relationship between clinical features, inflammatory biomarkers (C-reactive protein and procalcitonin, CRP and PCT, respectively), microbiological profiles, and outcomes in patients with sepsis with UTI. A secondary aim was to compare microbiological patterns between institutionalized patients and those living at home without known MDR risk factors.
methodsA retrospective cohort study was conducted on 231 patients with sepsis with UTI. admitted to the Infectious Diseases Unit of Chieti Hospital, Italy, between 2014 and 2024 (excluding 2020-2021). Data on clinical, laboratory, and microbiological variables were collected. MDR organisms were defined per European Centre for Disease Prevention and Control (ECDC) criteria. Analyses included non-parametric tests and logistic regression.
resultsMDR pathogens were identified in over 40% of cases. Patients from long-term care facilities had higher CRP levels and a higher prevalence of MDR infections. Carbapenems were frequently used, though empirical treatment was sometimes inappropriate. PCT did not differ significantly between MDR and non-MDR groups and had limited prognostic value. CRP and MDR presence were both associated with worse outcomes and longer hospital stays. Functional dependence and dementia were strongly linked to MDR infections. Age correlated with comorbidities but was not an independent predictor of outcome.
conclusionsMDR infections worsen the course of sepsis with UTI. CRP may outperform PCT in assessing severity, especially in institutionalized patients. Functional and cognitive impairments increase vulnerability to MDR pathogens. These findings support the need for rapid diagnostics, targeted antibiotic use, and personalized care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.